OSMT's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.3 -- higher than merely 5.58% of US-listed equities with positive expected earnings growth.
OSMT's went public 1.62 years ago, making it older than merely 2.46% of listed US stocks we're tracking.
Of note is the ratio of Osmotica Pharmaceuticals plc's sales and general administrative expense to its total operating expenses; just 11.61% of US stocks have a lower such ratio.
Stocks with similar financial metrics, market capitalization, and price volatility to Osmotica Pharmaceuticals plc are MNK, CPA, TIPT, NES, and RFP.
Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) Company Bio
Osmotica Pharmaceuticals Plc is a holding company engages in the development and commercialization of specialty products that target markets with underserved patient populations. It offers the M-72, Lorzone which is the chlorzoxazone scored tablets and ConZip which is tramadol hydrochloride extended-release capsules in specialty neurology; and OB Complete, which is the family of prescription prenatal dietary supplements, and Divigel in women's health. The company was founded on July 13, 2017 and is headquartered in Bridgewater, NJ.
OSMT Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Osmotica Pharmaceuticals plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Osmotica Pharmaceuticals plc ranked in the 13th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 86.17%. In terms of the factors that were most noteworthy in this DCF analysis for OSMT, they are:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 56. Notably, its equity weight is greater than merely 15.56% of US equities in the Healthcare sector yielding a positive free cash flow.
The company's compound free cash flow growth rate over the past 1.61 years comes in at -0.2%; that's greater than only 9.18% of US stocks we're applying DCF forecasting to.
Osmotica Pharmaceuticals plc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -15.47. This coverage rate is greater than that of only 5.61% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as OSMT, try IDXX, ICUI, MOH, QGEN, and A.
It has been almost three months since the coronavirus-driven volatility hit the global economy, and the market continues to rapidly move into both the green and the red. Yet, since its March 16 low, the S&P 500 has come a long way, rising nearly 18%. Wall Street pros remind investors that one area of the market has performed significantly better than the S&P 500: the biotech sector. As a result, names inhabiting this space have found themselves under the Street’s microscope.Having said that, there is something to consider when making these investment decisions. Biotech stocks are especially volatile due to the characteristics of the industry itself. For these companies, there are only a few key indicators like study results or regulatory approvals to determine whether or not sustainable...